Aeglea BioTherapeutics
year data from phase open label extension study of in deficiency patients | Aeglea BioTherapeutics
Company
Deck Type
Sector
Industry
Deck date
June 2020
Slide
8 of 22
Similar slides by Aeglea BioTherapeutics
See diffirences between slides (animation)
Investor Presentation
August 2020
year data from phase open label extension study of in deficiency patients | Aeglea BioTherapeutics
Results
May 2020
characteristics safety summary | Aeglea BioTherapeutics
Related slides by other companies
Compass Therapeutics
Investor Presentation
May 2022
phase combination safety data | Compass Therapeutics
BioNTech
Results
November 2020
safety trial in patients with malignant solid tumors who are not bot | BioNTech
BioNTech
Results
November 2020
phase a safety profile | BioNTech
RenovoRx
IPO
August 2021
promising data from phase and observational registry studies advanced clinical development program to phase | RenovoRx
Other recent decks by Aeglea BioTherapeutics
See all presentations (14 decks)
Investor Presentation
October 2023
Investor Presentation
October 2023
Investor Presentation
September 2023
Investor Presentation
July 2023
Search Thousands of Presentations by World Leading Companies
Trending:
Addressable Market
Ecosystem
Beauty Market
WACC
NFT
Management Team
Investment Highlights

Stay in the loop

Join our mailing list to stay in the loop with updates and newest feature releases

Presentations

Start Up
IPO
SPAC
M&A
Investor Day
Results
ESG
Credit
Investment Banking

Explore

Presentation Collections
Slide Collections

Company

Blog
Contact us
© 2021-2023 Slidebook.io